GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: MP5D2_CL22A3 | UCB-6114
Compound class:
Antibody
Comment: Ginisortamab (UCB6114) is a human IgG4κ monoclonal antibody that targets the endogenous BMP antagonist peptide gremlin 1. The heavy and light chain peptide sequences of ginisortamab are claimed in UCB Biopharma's patent WO2018115017A2 [1].The patent describes their antibodies as allosteric modulators, whose epitope is distal to the BMP binding site of gremlin 1.
|
| No information available. |
Summary of Clinical Use  |
| Ginisortamab (UCB6114) has advanced to early stage clinical evaluation for anti-tumour efficacy in advanced solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04393298 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Phase 1/Phase 2 Interventional | UCB Pharma | ||
